Data Support Adjuvant Pembrolizumab as Standard Care in Stage IIB/C Melanoma

Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, updated data suggest.

Related Keywords

Pennsylvania ,United States ,Jasonj Luke , ,Merck Sharp Dohme ,Hillman Cancer Center ,Cancer Center ,Merck Sharp ,